Navigation Links
BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
Date:1/28/2009

NOVATO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 18, at 5:00 p.m. ET (23:00 CET) to discuss fourth quarter and full year 2008 financial results.

    U.S. / Canada Dial-in Number:  866.700.6293
    International Dial-in Number:  617.213.8835
    Participant Code: 35749059
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 73992450

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

    Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

     Contacts:

     Investors                         Media
     Eugenia Shen                      Susan Berg
     BioMarin Pharmaceutical Inc.      BioMarin Pharmaceutical Inc.
     (415) 506-6570                    (415) 506-6594

'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin to Present at the Piper Jaffray Healthcare Conference
2. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
3. BioMarin to Present at the Credit Suisse Healthcare Conference
4. BioMarin Announces Third Quarter 2008 Financial Results
5. BioMarin Corrects Information Included in Bloomberg Article
6. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
7. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
8. BioMarin to Present at the Citi Biotech Day
9. BioMarin Announces Roll-Out of National PKU Registry
10. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
11. BioMarin to Present at the Collins Stewart Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2017)... ... June 15, 2017 , ... ... (EKG) follows an artist’s journey through creative experimentation and interdisciplinary collaboration. Feature Creep, ... through July 22nd. An opening reception will be held at EKG, located at ...
(Date:6/14/2017)... ... June 14, 2017 , ... The Thailand Board of Investment ... they’re co-hosting a delegation from Thailand at BIO 2017 in San Diego, CA ... in the world, regroups more than 1,100 biotech companies, academic institutions, state biotechnology ...
(Date:6/14/2017)... , June 14, 2017   Micralyne Inc., ... and a primary supplier of sensors, is pleased ... Placentia, California to develop and ... (TSV).  The joint development of this technology leverages ... a truly flexible and cost effective Metal TSV ...
(Date:6/13/2017)... MA (PRWEB) , ... June ... ... a leading international supplier of advanced flexible materials, has chosen The Copley ... a significant growth trajectory, Boyd Technologies is aligning its manufacturing operations and ...
Breaking Biology Technology:
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
Breaking Biology News(10 mins):